[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345238-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345238-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","wtap-stabilized-by-usp7-contributes-to-enzalutamide-resistance-in-prostate-cancer-via-mediating-akt-m6a-modication","WTAP stabilized by USP7 contributes to enzalutamide resistance in prostate cancer via mediating AKT m6A-modiﬁcation","","Castration-resistant prostate cancer (CRPC) patients treated with the androgen receptor inhibitor enzalutamide eventually develop acquired enzalutamide resistance (ENZR). This study examines the role of Wilms’ tumor 1-associating protein (WTAP) in resistance. Using patient tissue microarrays, WTAP is found upregulated in prostate cancer and promotes proliferation and tumor growth. WTAP is identified as an AR-responsive gene, increases in ENZR cells, and WTAP knockdown suppresses ENZR proliferation. Mechanistically, USP7 stabilizes WTAP via the ubiquitin-proteasome pathway, enhances AKT signaling via m6A-mediated regulation, and an AKT inhibitor reverses the WTAP-driven pro-resistance phenotype.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/wtap-stabilized-by-usp7-contributes-to-enzalutamide-resistance-in-prostate-cancer-via-mediating-akt-m6a-modication/345238/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/wtap-stabilized-by-usp7-contributes-to-enzalutamide-resistance-in-prostate-cancer-via-mediating-akt-m6a-modication/345238.png","ImageObject",300,407,{"name":42,"@type":43},"Noah","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address in prostate cancer treatment?","Question",{"text":63,"@type":64},"It addresses the acquired enzalutamide resistance that emerges in castration-resistant prostate cancer patients and the lack of clear mechanisms driving that resistance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is WTAP implicated in prostate cancer and enzalutamide resistance?",{"text":68,"@type":64},"WTAP is upregulated in prostate cancer, promotes proliferation and tumor growth, is an AR-responsive gene, and is further upregulated in ENZR cells where WTAP knockdown inhibits cell proliferation.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanism links USP7, WTAP, and AKT signaling to resistance?",{"text":72,"@type":64},"USP7 enhances WTAP stability through the ubiquitin-proteasome pathway in ENZR cells, leading to increased AKT signaling via an m6A-mediated process; AKT inhibition abolishes the pro-resistance phenotype driven by WTAP.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345238,1790104102,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":113,"preview_page_count":33,"preview_urls":146},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","Cancer Gene [Therapy](Therapy www.nature.com/cgt)[ www.nature.com/cgt](Therapy www.nature.com/cgt)  \nARTICLE OPEN   \nWTAP stabilized by USP7 contributes to enzalutamide resistance in prostate cancer via mediating AKT m6A-modiﬁcation  \n© The Author(s) 2026  \n\n|  |  |  |\n| --- | --- | --- |\n|  | Castration-resistant prostate cancer (CRPC) is one of the most prevalent cancers in men. The new generation androgen receptor (AR) inhibitor enzalutamide can improve the therapeutic effectiveness of patients with CRPC. However, these patients eventually develop acquired enzalutamide resistance (ENZR), and the mechanisms underlying resistance are not well understood. Wilms’ tumor 1-associating protein (WTAP) plays an important role in m6A modiﬁcation and has been reported as an oncogene in various cancers. Here, we utilized a tissue microarray and collected tissues from prostate cancer (PCa) patients to detect WTAP expression, and found that WTAP is upregulated in PCa. Meanwhile, WTAP overexpression promotes cell proliferation and accelerates tumor growth through colony formation assays and the establishment of a subcutaneous xenograft model in vivo. These ﬁndings establish the tumor promoter role of WTAP in prostatic tumorigenesis. Furthermore, we veriﬁed that WTAP is a novel responsive gene of AR via promoter activity and chromatin immunoprecipitation (ChIP) assays. Importantly, we uncovered that WTAP is upregulated in ENZR cells, and WTAP knockdown inhibited the proliferation of ENZR cells. Mechanistically, ubiquitin-speciﬁc protease (USP7) enhanced the stability of WTAP by the ubiquitin-proteasome pathway in ENZR cells, thereby WTAP increases promote AKT signaling through an m6A-mediated way, and an AKT inhibitor can abolish the pro-resistance phenotype mediated by WTAP. Together, these ﬁndings suggest that WTAP plays a key role in ENZR development of PCa cells, and WTAP may be a potential treatment target for ENZR tumors.\u003Cbr>Cancer Gene Therapy (2026) 33:277–288; [https://doi.org/10.1038/s41417-026-01013-y](https://doi.org/10.1038/s41417-026-01013-y) |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| |  | |\n\nGraphical Abstract  \nIn this manuscript, we utilized a tissue microarray and collected tissues from prostate cancer (PCa) patients to detect WTAP expression, and found that WTAP is upregulated in PCa. Meanwhile, WTAP overexpression promotes cell proliferation and accelerates tumor growth through colony formation assays and the establishment of a subcutaneous xenograft model in vivo. These ﬁndings establish the tumor promoter role of WTAP in prostatic tumorigenesis. Furthermore, we veriﬁed that WTAP is a novel responsive gene of AR via promoter activity and chromatin immunoprecipitation (ChIP) assays. Importantly, we uncovered that WTAP is upregulated in ENZR cells, and WTAP knockdown inhibited the proliferation of ENZR cells. Mechanistically, ubiquitin-speciﬁc protease (USP7) enhanced the stability of WTAP by the ubiquitin-proteasome pathway in ENZR cells, thereby WTAP increases promote AKT signaling through an m6A-mediated way, and an AKT inhibitor can abolish the pro-resistance phenotype mediated by WTAP. Together, these ﬁndings suggest that WTAP plays a key role in ENZR development of PCa cells, and WTAP may be a potential treatment target for ENZR tumors.  \nA full list of authors and their afﬁliations appears at the end of the paper.  \nReceived: 30 August 2025 Revised: 9 January 2026 Accepted: 5 February 2026  \nPublished online: 14 April 2026  \nR. Shi et al.  \n278  \nINTRODUCTION  \nProstate cancer (PCa) is one of the most prevalent cancers and is ranked as the second most lethal threat of malignant tumors in men [1] . Androgen receptor (AR) plays a central role in the PCa progression and serves as a decisive part in the treatment of PCa patients. Androgen deprivation therapy (ADT) as a mainstay in treating advanced PCa has been s","cbCaihA4Ct4AlybV","https://ap.wps.com/l/cbCaihA4Ct4AlybV","pdf",7008327,12,"English","# Introduction\n## Castration-resistant prostate cancer and enzalutamide resistance\n## Role of AKT signaling\n## WTAP and m6A regulation","[{\"question\":\"What problem does the study address in prostate cancer treatment?\",\"answer\":\"It addresses the acquired enzalutamide resistance that emerges in castration-resistant prostate cancer patients and the lack of clear mechanisms driving that resistance.\"},{\"question\":\"How is WTAP implicated in prostate cancer and enzalutamide resistance?\",\"answer\":\"WTAP is upregulated in prostate cancer, promotes proliferation and tumor growth, is an AR-responsive gene, and is further upregulated in ENZR cells where WTAP knockdown inhibits cell proliferation.\"},{\"question\":\"What mechanism links USP7, WTAP, and AKT signaling to resistance?\",\"answer\":\"USP7 enhances WTAP stability through the ubiquitin-proteasome pathway in ENZR cells, leading to increased AKT signaling via an m6A-mediated process; AKT inhibition abolishes the pro-resistance phenotype driven by WTAP.\"}]","WTAP stabilized by USP7 contributes to enzalutamide resistance in prostate cancer via mediating AKT m6A-modiﬁcation | PDF",1790056921,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e80582270e9bec9d471845f9661d6d1.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61553d902d7011e19812fda8eec95f9c.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe24574792e1932b40a84e6a7bd4f3d9.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd517e449f4644ad293380c0010cb59c.webp",980,1301]